Regenxbio Inc (NASDAQ:RGNX) Holdings Trimmed by California State Teachers Retirement System

California State Teachers Retirement System cut its holdings in Regenxbio Inc (NASDAQ:RGNX) by 9.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,022 shares of the biotechnology company’s stock after selling 4,753 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Regenxbio worth $1,451,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RGNX. Schwab Charles Investment Management Inc. boosted its position in Regenxbio by 32.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 97,695 shares of the biotechnology company’s stock worth $1,930,000 after acquiring an additional 23,971 shares during the last quarter. Rhumbline Advisers boosted its position in Regenxbio by 45.5% during the second quarter. Rhumbline Advisers now owns 27,251 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 8,520 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Regenxbio by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 177,277 shares of the biotechnology company’s stock worth $3,501,000 after acquiring an additional 30,725 shares during the last quarter. Legal & General Group Plc boosted its position in Regenxbio by 41.4% during the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 2,011 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Regenxbio by 1.1% during the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 175 shares during the last quarter. Institutional investors and hedge funds own 68.66% of the company’s stock.

RGNX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research note on Wednesday, October 18th. Chardan Capital increased their price target on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Morgan Stanley reaffirmed an “overweight” rating and set a $34.00 price target on shares of Regenxbio in a research note on Thursday, November 9th. ValuEngine downgraded shares of Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Finally, Barclays began coverage on shares of Regenxbio in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $38.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $40.63.

Regenxbio Inc (NASDAQ RGNX) traded up $0.20 on Wednesday, reaching $26.80. 268,140 shares of the company were exchanged, compared to its average volume of 447,992. The firm has a market cap of $834.69 and a price-to-earnings ratio of -9.89. Regenxbio Inc has a 1-year low of $16.30 and a 1-year high of $36.45.

In related news, CFO Vittal Vasista sold 5,000 shares of the firm’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief financial officer now directly owns 87,277 shares of the company’s stock, valued at approximately $2,618,310. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Curran Simpson sold 2,000 shares of the firm’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $29.31, for a total transaction of $58,620.00. Following the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $1,216,365. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 94,000 shares of company stock valued at $2,879,096. Company insiders own 17.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/regenxbio-inc-rgnx-shares-sold-by-california-state-teachers-retirement-system.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply